IP Library Granted Patent US 9,732,327
Granted Patent B2
US 9,732,327 · App. 14/604,018 · Granted Aug 15, 2017

Formulation of sugar solutions for continuous ultracentrifugation for virus purification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,732,327
App. No.
14/604,018
Granted
Aug 15, 2017
Kind
B2
Abstract

The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.

Claims (34)

1. A method for purifying a virus, comprising

providing

(i) a buffered sugar solution having a density of 1.15 kg/l to 1.23 kg/l and comprising a first physiological buffer and

(ii) a buffered sugar solution having a density of 1.23 kg/l to 1.32 kg/l and which is higher than the buffered sugar solution (i), and comprising a physiological buffer which is the same or different from the physiological buffer of (i),

wherein the volume ratio of buffered sugar solution (i) to buffered sugar solution (ii) is greater than or equal to 3:1;

providing a virus preparation;

centrifuging the virus preparation and buffered sugar solutions (i) and (ii) in a ultracentrifuge comprising an ultracentrifuge rotor to obtain a peak pool; and

extracting the peak pool to obtain the virus.

2. The method of claim 1 , wherein the volume of buffered sugar solutions (i) and (ii) is between 5% to 100% of the volume of the ultracentrifugation rotor.

3. The method of claim 1 , wherein the peak pool has a density between 1.20 kg/l to 1.24 kg/l.

4. The method of claim 1 , wherein one of said buffers has a concentration of between 5 mM to 50 mM.

5. The method of claim 4 , wherein said buffer has a concentration of between 15 mM to 30 mM.

6. The method of claim 5 , wherein said buffer has a concentration of between 18 mM to 25 mM.

7. The method of claim 1 , wherein the step of centrifuging the virus preparation and buffered sugar solutions is performed with a relative centrifugation of at least 20,000 g.

8. The method of claim 7 , wherein said relative centrifugation force is at least 30,000 g.

9. The method of claim 8 , wherein said relative centrifugation force is at least 90,000 g.

10. The method of claim 1 , wherein said volume ratio of said buffered sugar solution (i) to said buffered sugar solution (ii) is less than 20:1.

11. The method of claim 10 , wherein said volume ratio is less than 10:1.

12. The method of claim 11 , wherein said volume ratio is less than 8:1.

13. The method of claim 12 , wherein said volume ratio is between 6:1 to 3:1.

14. The method of claim 1 , wherein the virus preparation is obtained by centrifugation without a preclarifier.

15. The method of claim 1 , wherein said virus preparation comprises cells inoculated with the virus.

16. The method of claim 15 , wherein said cells are of an animal cell culture or cell line.

17. The method of claim 15 , wherein said cells are epithelial cells.

18. The method of claim 17 , wherein said cells are kidney epithelial cells.

19. The method of claim 18 , wherein said cells are Vero cells.

20. The method of claim 1 , wherein at least one of the physiological buffers is an amine buffer.

21. The method of claim 20 , wherein at least one of the physiological buffers is a trishydroxymethylaminomethane (TRIS) buffer.

22. The method of claim 21 , wherein the physiological buffer is TRIS-buffered saline.

23. The method of claim 1 , wherein the volume of buffered sugar solutions (i) and (ii) is less than 100% of the volume of the ultracentrifuge rotor.

24. The method of claim 23 , wherein the volume of buffered sugar solutions (i) and (ii) is less than 90% of the volume of the ultracentrifuge rotor.

25. The method of claim 1 , wherein the volume of buffered sugar solutions (i) and (ii) is greater than or equal to 50% of the volume of the ultracentrifuge rotor.

26. The method of claim 24 , wherein the volume of buffered sugar solutions (i) and (ii) is less than 90% of the volume of the ultracentrifuge rotor.

27. The method of claim 1 , wherein the virus is a parvovirus.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2022
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 059895/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2016
From: REITER, MANFRED; GRILLBERGER, LEOPOLD; MUNDT, WOLFGANG; MITTERER, ARTUR; SCHAFHAUSER, HORST
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 040151/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036374/0001 →